Influenza and oseltamivir phosphate (Tamiflu) in infants: what you need to know
Insights
Influenza poses significant risks to young children, especially infants. Oseltamivir phosphate (Tamiflu) is now approved for treating uncomplicated influenza in children two weeks and older, requiring careful monitoring by healthcare providers.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Influenza causes substantial hospitalizations and deaths in children under five.
- Infants and young children, particularly those under six months, face the highest risk of influenza complications.
- Current influenza vaccines have reduced efficacy in children under two and are not approved for infants under six months.
Purpose of the Study:
- To review the efficacy and safety of oseltamivir phosphate (Tamiflu) for treating uncomplicated influenza in young children.
- To highlight the importance of appropriate dosing, adverse reaction monitoring, and patient education for this vulnerable population.
Main Methods:
- Review of current research on influenza in pediatric populations.
- Analysis of the U.S. Food and Drug Administration (FDA) approval of oseltamivir phosphate for infants and young children.
- Discussion of clinical considerations for healthcare providers.
Main Results:
- Oseltamivir phosphate (Tamiflu) is now approved for treating uncomplicated influenza in patients two weeks of age and older.
- Young children are susceptible to both the benefits and risks associated with oseltamivir phosphate.
- Healthcare providers need to be informed about dosing, adverse reactions, and monitoring parameters.
Conclusions:
- Oseltamivir phosphate offers a treatment option for influenza in young children, but careful management is essential.
- Awareness of drug benefits, risks, and proper monitoring is crucial for pediatric influenza treatment.
- Further research and clinical vigilance are necessary to ensure the safe and effective use of oseltamivir phosphate in infants and young children.
Abstract:
Influenza is a highly contagious virus that causes an average of 20,000 hospitalizations a year in children under five years of age. As of March 30, 2013, the 2012-2013 flu season had seen 111 pediatric deaths, with 21 deaths in the 0- to 23-month-old range. Rates of influenza-associated hospitalization are substantially higher among infants and young children than among older children, and those under six months old are at the highest risk. Research shows that influenza vaccine is not as effective in children two years of age relative to adults, and the vaccine is not approved in infants younger than six months. Thus, preventing influenza and proper treatment are important for keeping this high-risk group safe from complications. With infants being highest at risk for complications and the extrapolation of efficacy and safety from the older population, the U.S. Food and Drug Administration (FDA) recently approved the use of the antiviral oseltamivir phosphate (Tamiflu) for treatment of uncomplicated influenza in patients two weeks and older. This young population is susceptible to the benefits as well as the risks of the drug. Health care providers must be aware of dosing, adverse reactions, and monitoring parameters to better treat and educate their patients.
Related Concept Videos
01:27Influenza
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:29Drug Dosing: Infants and Children
01:30Inhibitors of Viral Protein Synthesis
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
01:51Vaccinations